159 related articles for article (PubMed ID: 29251173)
1. Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.
Lucarini L; Magnelli L; Schiavone N; Crisci A; Innocenti A; Puccetti L; Cianchi F; Peri S; Supuran CT; Papucci L; Masini E
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):234-240. PubMed ID: 29251173
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Giménez-Bachs JM; Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SH; Rubio-Del Campo A; Sánchez-Prieto R
Scand J Urol Nephrol; 2012 Oct; 46(5):358-64. PubMed ID: 22571179
[TBL] [Abstract][Full Text] [Related]
3. Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
Lin XY; Zhang H; Tang N; Zhang XP; Zhang W; Wang EH; Han YC
Histopathology; 2015 Apr; 66(5):685-94. PubMed ID: 25431204
[TBL] [Abstract][Full Text] [Related]
4. Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.
Young JR; Coy H; Kim HJ; Douek M; Sisk A; Belldegrun A; Pantuck AJ; Raman SS
Abdom Radiol (NY); 2018 Oct; 43(10):2734-2742. PubMed ID: 29520426
[TBL] [Abstract][Full Text] [Related]
5. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
6. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
[TBL] [Abstract][Full Text] [Related]
7. hERG1 and CA IX expression are associated with disease recurrence in surgically resected clear cell renal carcinoma.
Lastraioli E; Pillozzi S; Mari A; Tellini R; Duranti C; Baldazzi V; Venturini S; Minervini A; Lapini A; Nesi G; Carini M; Arcangeli A
Eur J Surg Oncol; 2020 Jan; 46(1):209-215. PubMed ID: 31679954
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Ambrosio MR; Di Serio C; Danza G; Rocca BJ; Ginori A; Prudovsky I; Marchionni N; Del Vecchio MT; Tarantini F
Diagn Pathol; 2016 May; 11(1):45. PubMed ID: 27225200
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia Marker Carbonic Anhydrase IX Is Present in Abdominal Aortic Aneurysm Tissue and Plasma.
Grossmannova K; Barathova M; Belvoncikova P; Lauko V; Csaderova L; Tomka J; Dulka T; Pastorek J; Madaric J
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055064
[TBL] [Abstract][Full Text] [Related]
10. Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.
Li Y; Dong M; Sheng W; Huang L
Pathol Oncol Res; 2016 Apr; 22(2):277-86. PubMed ID: 26224207
[TBL] [Abstract][Full Text] [Related]
11. Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
Logozzi M; Mizzoni D; Capasso C; Del Prete S; Di Raimo R; Falchi M; Angelini DF; Sciarra A; Maggi M; Supuran CT; Fais S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):280-288. PubMed ID: 31790614
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells.
Cianchi F; Vinci MC; Supuran CT; Peruzzi B; De Giuli P; Fasolis G; Perigli G; Pastorekova S; Papucci L; Pini A; Masini E; Puccetti L
J Pharmacol Exp Ther; 2010 Sep; 334(3):710-9. PubMed ID: 20519553
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy.
Vidlickova I; Dequiedt F; Jelenska L; Sedlakova O; Pastorek M; Stuchlik S; Pastorek J; Zatovicova M; Pastorekova S
BMC Cancer; 2016 Mar; 16():239. PubMed ID: 26993100
[TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer.
Eldehna WM; Nocentini A; Al-Rashood ST; Hassan GS; Alkahtani HM; Almehizia AA; Reda AM; Abdel-Aziz HA; Supuran CT
Bioorg Chem; 2018 Dec; 81():425-432. PubMed ID: 30219719
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition.
Mboge MY; Chen Z; Wolff A; Mathias JV; Tu C; Brown KD; Bozdag M; Carta F; Supuran CT; McKenna R; Frost SC
PLoS One; 2018; 13(11):e0207417. PubMed ID: 30452451
[TBL] [Abstract][Full Text] [Related]
17. Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
Papworth K; Sandlund J; Grankvist K; Ljungberg B; Rasmuson T
Anticancer Res; 2010 Jul; 30(7):2953-7. PubMed ID: 20683038
[TBL] [Abstract][Full Text] [Related]
18. Acetazolamide-based [
More KN; Lee JY; Kim DY; Cho NC; Pyo A; Yun M; Kim HS; Kim H; Ko K; Park JH; Chang DJ
Bioorg Med Chem Lett; 2018 Mar; 28(5):915-921. PubMed ID: 29422388
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
20. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Alsaab HO; Sau S; Alzhrani RM; Cheriyan VT; Polin LA; Vaishampayan U; Rishi AK; Iyer AK
Biomaterials; 2018 Nov; 183():280-294. PubMed ID: 30179778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
